Bristol-Myers Squibb (BMY) won the dismissal of a proposed class-action lawsuit in a federal court accusing it of using anticompetitive tactics to maintain monopoly on its blood cancer drug Pomalyst, multiple media outlets reported Wednesday.

US District Judge Edgardo Ramos in New York City said in a 70-page decision that Blue Cross Blue Shield of Louisiana and other Pomalyst purchasers failed to show that the company violated the federal Sherman act, Reuters reported.

Filed in September 2023, the suit claimed the drug to have been subject to generic competition by October 2020 and Bristol-Myers' tactics caused these companies to overpay by hundreds of millions, Fierce Pharma reported.

The lawsuit accused Bristol-Myers of obtaining illegal patents to the drug and then in order to maintain a monopoly filing sham lawsuits against generic drugmakers.

Price: 53.12, Change: +0.05, Percent Change: +0.09